Please login to the form below

Not currently logged in
Email:
Password:

Top three therapeutic areas lead pharma’s pipeline

Oncology dominates followed by CNS disorders and infectious diseases

GBI ResearchOncology, central nervous system (CNS) disorders and infectious diseases account for 68% of the overall pharmaceutical industry pipeline, according to a new market research report.

Undertaken by GBI Research, the findings show that the top three therapeutic areas constitute the majority of drugs actively under development as of the first quarter of 2016, with oncology the largest therapy area by far.

Almost 7,000 new cancer products are in the works, nearly double the respective totals of CNS and infectious disease products currently lined up.

Managing analyst for GBI Research Dominic Trewartha said this industry-wide trend is due to the “substantial patient populations and strong unmet needs within the indications that account for the majority of patients in each areas”.

He added that the rapid expansion in oncology in particular was fed by pipeline growth in breast, colorectal and lung cancer - the area's three largest indications - each of which increased by over 15%.

The report - called Innovation Tracking Factbook 2016 - also found that the pipeline activity for the pharmaceutical industry as a whole increased by 5% this year, with the majority of major indications having grown in comparison with 2015.

Cardiovascular diseases, immunology and metabolic disorders, for example, each have over 1,000 products in pipelines.

The vast majority of pipeline products are currently in early-stage development and are yet to demonstrate both safety and efficacy, however the sheer size of the overall pipeline indicates “a steady stream of incremental and breakthrough innovation” across markets in the near future, Trewartha concluded.

Article by
Rebecca Clifford

29th July 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics